25 September 2023
25 September 2023
In the EMPA-KIDNEY study, Jardiance achieved a 28% reduction in relative risk compared to placebo.
The biopharma giant's decision to end its partnership with I-Mab follows it ending a trial for the drug early.
Currently, eight states in the US demand that health insurance plans cover OTC contraceptives.
The regulator granted approval based on data from the Phase III ASTRUM-007 trial of serplulimab plus chemotherapy.
Valneva is responsible for marketing and supplying the vaccine directly to the military and private travel market in the US.
Merck will provide funds for nine full-time research positions at the institute.
A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.
The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
